Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss [Yahoo! Finance]
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA [Yahoo! Finance]
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA